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Use of Intraoperative Samples to
Optimize Efficacy of Central
Laboratory Parathyroid Hormone
Analyses
To the Editor:
Intact (1-84) parathyroid hormone
(PTH) has a short half-life and can be
monitored during surgery to confirm
the removal of all hyperfunctioning
parathyroid tissue, but exact criteria
for timing of sample collection and
number of samples that best indicate
a surgical cure are still to be perfected
(1). We report the degree of accuracy
of our protocol of performing only 2
intraoperative PTH tests in patients
undergoing parathyroidectomy.
Sixty patients (43 women, 17 men;
mean age 59.8 years, range 22–79
years), without renal failure, who
underwent a minimally invasive sur-
gical operation for sporadic primary
hyperparathyroidism, participated
in the study. Blood was collected
from a peripheral vein before skin
incision (basal or t-0) and 10 min
after parathyroidectomy (t-10). The
removal of the hyperfunctioning
gland(s) was considered effective
when the PTH decrease was 50%
from the t-0 value (2 ). We measured
the t-0 concentration before skin in-
cision because physical manipulation
of the parathyroid glands during sur-
gery often leads to false increases in
PTH concentrations. Thus baseline
PTH obtained after incision may be
falsely increased, and PTH may
show a misleading decrease and ap-
pear to meet cutoff criteria compared
with the t-10 concentration, which
might actually represent the true
baseline PTH (3 ). When t-10 PTH did
not decrease, we collected another
blood sample, generally 35 min after
parathyroidectomy (t-35). While
awaiting the result of the last sample,
we performed bilateral neck explora-
tion and removed any enlarged
glands. A subtotal parathyroidec-
tomy was performed if the last sam-
ple did not show a PTH decrease or
no other adenomas were found.
We measured PTHwith an electro-
chemiluminescence immunoassay
(Roche Diagnostics) performed on an
Elecsys-2010 (Roche Diagnostics).
The PTH assay detection limit was
1.2 ng/L, the assay analytical range
was 1.2–5000 ng/L, and the reference
interval was 15–65 ng/L. The total
imprecision values (n  12) were
5.9% and 4.3% at PTH concentrations
of 1.8 ng/L and 11.7 ng/L, respec-
tively. The definition of operative
success was eucalcemia for 6 months
or longer after parathyroidectomy
(4 ).
With a considerable decrease of
PTH concentration of 50% at t-10,
the procedure had 1 (1.5%) false pos-
itive, 5 (8%) false negatives, 8 (13%)
true negatives, and 46 (77%) true
positives with 90% sensitivity, 89%
specificity, 98% positive predictive
value, 62% negative predictive value,
and 90% overall accuracy. For the
false positive result, the PTH de-
crease was 72%, and for the false
negatives, true negatives, and true
positives, respectively, the median
(range) PTH decreases were 27%
(5%–42%), 16% (5%–33%), and 82%
(53%–92%). Considering the decrease
at t-35, for the patients without a
PTH decrease of 50%, the proce-
dure had 1 (1.5%) false positive, 0
false negative, 0 true negative, and 59
(98.5%) true positives. The median
(range) PTH decrease was 81% (53%–
94%) for the true positives. In 59 of 60
patients the presented protocol led to
correct prediction of postoperative
eucalcemia with 100% sensitivity,
98.5% positive predictive value, and
98.5% overall accuracy. Thus the
rapid PTH assay correctly identified
all but 1 case of solitary adenoma
and of multigland disease, including
3 cases of hyperplasia.
Because the last sample must be
collected 10 min after excision and
transport of samples to the labora-
tory took 5 min, the average total
waiting time after parathyroidec-
tomy was 35 min.
The cost of 2 intraoperative PTH
determinations was $13.28 on the
Elecsys-2010 already in use in the
laboratory. The cost with a STAT-
IntraOperative-System (Future Diag-
nostics), was $1035.51 (2 samples and
6 calibrators plus 2 controls, all per-
formed in duplicate) with 15 min of
processing time making a total of 25
min after the parathyroidectomy.
Thus, the overall costs for a paired
intraoperative PTH assay were
$89.86 ($13.28 for the reagents and
$76.58 for the operating room, allow-
ing for an additional 10 min awaiting
laboratory results) and $1059.94
($1035.51 for the reagents and $24.43
for 2 h of technician time) when
performed in the laboratory and in
the operating theater, respectively. If
the intervention lasted until t-35, the
overall costs for 3 intraoperative
PTH assays was $96.49 ($19.91 for
the reagents and $76.58 for 10 min
use of the operating room) and
$1194.63 ($1164.10 for the reagents
and $30.53 for 2.5 h of technician
time) when performed in the labora-
tory and in the operating theater,
respectively.
The suggested procedure with
only 2 intraoperative PTH tests per-
formed in the laboratory seems the
most appropriate to obtain the high-
est quality results at the lowest cost if
the laboratory is in close proximity to
the surgical site (transport time of 5
min).
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Monitoring Blood Glucose with
Microdialysis of Interstitial Fluid in
Critically Ill Children
To the Editor:
Hyperglycemia, a common feature in
critically ill patients, was tradition-
ally perceived as an adequate stress
response reflecting the severity of the
disease state and was treated only if
glycemia exceeded 11–13.5 mmol/L.
In recent studies in intensive care
patients, we showed that tight glyce-
mic control (TGC) with intensive in-
sulin therapy (IIT) reduced the risk
of organ failure and death (1 ). In
critically ill children, peak blood glu-
cose (BG) and duration of hyper-
glycemia are associated with risk of
mortality (2 ). Implementing TGC
and avoiding hypoglycemia with in-
tensive insulin therapy requires fre-
quent BG sampling. Microdialysis
of interstitial fluid (ISF) is a promis-
ing approach to reduce diagnostic
blood loss. Continuously sampling
dialyzed ISF and converting the ISF
glucose concentration (IFG) to a BG
value is a promising new method
for glucose monitoring in diabetes
patients. We conducted a prospec-
tive clinical trial in critically ill chil-
dren to evaluate the feasibility of
prolonged subcutaneous microdialy-
sis and the correlation between BG
and IFG.
The study was approved by the
Institutional Ethical Review Board.
Twenty children were enrolled after
written informed consent was ob-
tained from the parents. A CMA 60
microdialysis catheter (CMA Micro-
dialysis) was inserted subcutane-
ously. This catheter has a dialyzing
membrane with a molecular cutoff of
20 kDa and was continuously per-
fused with a 5% mannitol solution at
a flow rate of 1 L/min. BG was
determined on an ABL 715 blood gas
analyzer (Radiometer) and dialysate
glucose (DG) values with a Cobas
Mira Analyzer (Roche). Both tech-
niques use the enzyme glucose dehy-
drogenase. Because of the used flow
rate of 1 L/min, the concentration
in the dialysate reaches only partial
equilibration and thus does not re-
flect the absolute concentration in the
extracellular fluid. Therefore, IFG
was calculated using the ionic refer-
ence technique (3 ). This technique is
based on the simultaneous measure-
ment of glucose and ions in the sam-
ples. The ionic recovery can be calcu-
lated as the ratio of sodium in the
sample to the sodium concentration
in plasma, using an ion-free perfus-
ate. Assuming that recovery rates of
glucose and sodium were the same,
we calculated the glucose concentra-
tion of the ISF as IFG  dialysate
glucose  plasma sodium/dialysate
sodium. Thus, the relative recovery
of a particular substance is the con-
centration of this substance in the
dialysate expressed as percentage of
the concentration of this substance in
the surrounding tissues. Mean age and
body weight were 3.4 years and 14.5
kg. No complications with the tech-
nique occurred. Median microdialysis
recovery rate was 89% (P25–75:79–94%).
Fig. 1. Bland–Altman analysis.
The bias is 29.4 mg/dL (1.6 mmol/L). This bias represents the mean of the systematic distribution of the
values. To achieve TGC, this bias of 29.4 mg/dL is inaccurate for safe clinical implementation in ICU. Bias SD
(1.96) represents the limits of agreement. A potential difference reaching between 105.8 and 46.9 mg/dL
(5.9 and 2.6 mmol/L) is unacceptable for clinical use in ICU-settings applying TGC.
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